gestonorone-caproate has been researched along with Premature-Birth* in 2 studies
1 review(s) available for gestonorone-caproate and Premature-Birth
Article | Year |
---|---|
Progestins for the prevention of spontaneous preterm birth: review and implications of recent studies.
Progesterone plays a central role in the mechanisms of parturition in many species. Despite remarkable advances in our understanding of this hormone's mechanism of action, its roles in human pregnancy maintenance and parturition are not fully appreciated. Proper scientific hypothesis testing of progestins to prevent preterm birth has been limited because of the issues that can plague interventional trials in obstetrics, including patient selection, choice of outcome and power. The largest studies enrolling patients with a history of prior preterm birth alone to prevent recurrence appear contradictory. In contrast, consistent evidence from one multinational trial and a secondary analysis of another suggests cervical length may serve to identify potential responders to this therapy. Finally, the safety of progestin administration is a legitimate concern and a meta-analysis justifies the need for further investigation of safety issues. This review presents recent findings regarding progestin therapy from both clinical and laboratory data and considers unresolved issues for use of these agents. Topics: Dose-Response Relationship, Drug; Female; Gestonorone Caproate; Humans; Kaplan-Meier Estimate; Pregnancy; Premature Birth; Progesterone; Progestins; Randomized Controlled Trials as Topic | 2009 |
1 other study(ies) available for gestonorone-caproate and Premature-Birth
Article | Year |
---|---|
Preterm birth prevention by 17 alpha-hydroxyprogesterone caproate vs. daily nursing surveillance.
To compare the incidence of spontaneous recurrent preterm delivery (SPTD) between women receiving 17 alpha-hydroxyprogesterone caproate (17P) and women receiving daily perinatal nursing surveillance (dPNS) with home uterine activity monitoring.. Women enrolled for dPNS or weekly nursing visits with 17P injection were eligible. Included were singletons with previous SPTD, without preterm labor (PTL), cerclage or vaginal bleeding and < 27 weeks at enrollment. 17P and dPNS patients were matched 1:1 by race, marital status, tobacco use and number of SPTDs. Primary study outcome was incidence of spontaneous PTD.. Data from 342 matched pairs were compared. Diagnosis of PTL (39.2% vs. 60.8%) and tocolytic use (12.9% vs. 49.7%) was decreased with 17P vs. dPNS (p < 0.001). The incidences of spontaneous PTD at < 32, 35 and 37 weeks were similar between the groups.. There was no difference in recurrent SPTD between women treated with 17P and those receiving dPNS. Topics: Adult; Female; Gestonorone Caproate; Home Care Services; Humans; Injections, Intramuscular; Monitoring, Ambulatory; Obstetric Labor, Premature; Pregnancy; Premature Birth; Progestins; Retrospective Studies; Young Adult | 2009 |